Literature DB >> 19427441

Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis.

Bethany A Austin1, Brendan Duffy, Carmela Tan, E Rene Rodriguez, Randall C Starling, Milind Y Desai.   

Abstract

Cardiac amyloidosis (CA) is generally associated with a poor prognosis and significantly increased mortality. We sought to identify predictors of longer-term survival in patients with endomyocardial biopsy (EMB)-documented CA. Forty-five consecutive patients with EMB-documented CA were studied from January 1998 to December 2003. Age, gender, New York Heart Association class, medications, presence of light-chain amyloid, and electrocardiographic voltage were recorded. Baseline left ventricular (LV) ejection fraction, deceleration time, diastolic function, LV mass, ventricular septal thickness, and myocardial performance index ([isovolumic contraction time + isovolumic relaxation time]/ejection time) were recorded. Mean age was 66 +/- 10 years with 34 men (76%). New York Heart Association class >II was noted in 26 patients (58%) and low voltage on electrocardiogram (S wave [lead V(1)] + R wave [lead V(5)] < or =15) in 12 (27%). Mean LV ejection fraction, ventricular septal thickness, and LV mass were 46 +/- 13%, 1.7 +/- 0.42 cm, and 303 +/- 114 g, respectively. Deceleration time < or =150 ms was found in 19 (42%) and myocardial performance index >0.6 in 15 (33%). At a median follow-up of 1.7 years, there were 25 deaths (56%). On univariate Kaplan-Meier analysis, New York Heart Association class >II, deceleration time <150 ms, and beta-blocker use were associated with increased mortality (log-rank statistic p values <0.001, <0.05, and 0.01, respectively). On Cox proportional hazard survival analysis, only New York Heart Association class was significantly associated with increased mortality (hazard ratio 3.92, 1.92 to 7.95, p = 0.0002). In conclusion, in patients with EMB-documented CA, longer-term survival is more strongly associated with New York Heart Association functional class compared with electrocardiographic and echocardiographic variables.

Entities:  

Mesh:

Year:  2009        PMID: 19427441     DOI: 10.1016/j.amjcard.2009.01.361

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

Review 1.  Echocardiographic evaluation of cardiac amyloid.

Authors:  Wendy Tsang; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

2.  Transradial left ventricular endomyocardial biopsy: assessment of safety and efficacy.

Authors:  Tim G Schäufele; Raphael Spittler; Artemisia Karagianni; Peter Ong; Karin Klingel; Reinhard Kandolf; Heiko Mahrholdt; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2015-04-02       Impact factor: 5.460

3.  Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.

Authors:  Roberta Mussinelli; Francesco Salinaro; Alessio Alogna; Michele Boldrini; Ambra Raimondi; Francesco Musca; Giovanni Palladini; Giampaolo Merlini; Stefano Perlini
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

4.  Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography.

Authors:  Lu Zhang; Xiao Zhou; Jing Wang; Yang Mu; Bohan Liu; Wenqing Lv; Ye Wang; Hongwei Liu; Hongbin Liu; Guang Zhi
Journal:  Int J Cardiovasc Imaging       Date:  2016-11-23       Impact factor: 2.357

5.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Authors:  Paolo Milani; Angela Dispenzieri; Christopher G Scott; Morie A Gertz; Stefano Perlini; Roberta Mussinelli; Martha Q Lacy; Francis K Buadi; Shaji Kumar; Mathew S Maurer; Giampaolo Merlini; Suzanne R Hayman; Nelson Leung; David Dingli; Kyle W Klarich; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Patricia A Pellikka; Yi L Hwa; Stephen R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Martha Grogan
Journal:  Circ Cardiovasc Imaging       Date:  2018-05       Impact factor: 7.792

6.  Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.

Authors:  Diego Bellavia; Patricia A Pellikka; Ghormallah B Al-Zahrani; Theodore P Abraham; Angela Dispenzieri; Chinami Miyazaki; Martha Lacy; Christopher G Scott; Jae K Oh; Fletcher A Miller
Journal:  J Am Soc Echocardiogr       Date:  2010-06       Impact factor: 5.251

7.  Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis.

Authors:  Zhongwei Cheng; Lin Kang; Zhuang Tian; Weiyun Chen; Wenjuan Guo; Jia Xu; Taibo Chen; Ligang Fang; Yong Zeng; Kang'an Cheng; Quan Fang
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-01       Impact factor: 1.468

8.  The findings of electrocardiography in patients with cardiac amyloidosis.

Authors:  Zhongwei Cheng; Kongbo Zhu; Zhuang Tian; Dachun Zhao; Quancai Cui; Quan Fang
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

9.  Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

Authors:  Shawn C Pun; Heather J Landau; Elyn R Riedel; Jonathan Jordan; Anthony F Yu; Hani Hassoun; Carol L Chen; Richard M Steingart; Jennifer E Liu
Journal:  J Am Soc Echocardiogr       Date:  2017-10-27       Impact factor: 5.251

Review 10.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.